Heparin-Induced Thrombocytopenia, Fifth Edition: (Fundamental and Clinical Cardiology)

Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most frequent and devastating adverse drug reactions encountered by physicians. This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of this condition. Identifying key signs and symptoms and providing clear intervention strategies—including the use of alternative anticoagulants to manage critical circumstances—this is an essential resource for all clinicians and a "must" for hematology consultants. Heparin-Induced Thrombocytopenia, Fifth Edition explores: Clinical and laboratory studies on HIT The immune basis and pathogenesis, animal models, and laboratory testing for HIT antibodies Clinical features, differential diagnosis, scoring systems, and frequency of HIT in diverse clinical settings, including pediatric patients Evidence-based guidelines for recognition, treatment, and prevention Actions that should and should not be taken after the identification of HIT Traditional and novel pharmacotherapies, current dosing guidelines, and the advantages and limitations of alternative anticoagulants Selection criteria from a variety of new treatment options, helping physicians determine which of these agents are safe and effective for their patients

Table of Contents:
History of Heparin-Induced Thrombocytopenia. Clinical Picture of Heparin-Induced Thrombocytopenia. Differential Diagnosis of Heparin-Induced Thrombocytopenia and Scoring Systems. Frequency of Heparin-Induced Thrombocytopenia. Nonimmune Heparin-Platelet Interactions: Implications for the Pathogenesis of Heparin-Induced Thrombocytopenia. Role of Heparin-Dependent Antigens in Immune Heparin-Induced Thrombocytopenia. Role of Sulfated Polysaccharides and other Polyanions in the Pathogenesis of Heparin-Induced Thrombocytopenia. Platelet and Leukocyte Fcγ Receptors in Heparin-Induced Thrombocytopenia. Cellular and Molecular Immunopathogenesis of Heparin-Induced Thrombocytopenia. Murine Models of Heparin-Induced Thrombocytopenia. Laboratory Testing for Heparin-Induced Thrombocytopenia. Treatment of Heparin-Induced Thrombocytopenia: An Overview. Argatroban Therapy in Heparin-Induced Thrombocytopenia. Recombinant Hirudin for the Treatment of Heparin-Induced Thrombocytopenia. Bivalirudin for the treatment of Heparin-Induced Thrombocytopenia. Danaparoid for the Treatment of Heparin-Induced Thrombocytopenia. Fondaparinux and Other Emerging Anticoagulants to Treat Heparin-Induced Thrombocytopenia. Hemodialysis in HIT. Management of Intraoperative Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery. Heparin-Coated Intravascular Devices and Heparin-Induced Thrombocytopenia. Heparin-Induced Thrombocytopenia in Children. A Clinician’s Perspective on Heparin-Induced Thrombocytopenia: Paradoxes, Myths, and Continuing Challenges.

About the Author :
Theodore E. Warkentin, MD, FACP, FRCPC is Professor in the Department of Pathology and Molecular Medicine, and the Department of Medicine, at McMaster University, Canada. Prof. Dr. Andreas Greinacher is Professor and Head of the Department of Transfusion Medicine and the Hemostasis Service at the Medical School and Hospital of the Ernst-Moritz-Arndt-University Greifswald, CEO and Chief of Staff of the University Hospital Greifswald, and Visiting Professor McMaster University Hamilton, Canada.